Curated News
By: NewsRamp Editorial Staff
September 22, 2026
TransCode Therapeutics Expands Global IP Portfolio with Key Patents
TLDR
- TransCode Therapeutics secures Australian and Japanese patents for siRNA cancer treatments, strengthening its global IP position in RNA therapeutics.
- TransCode Therapeutics received patent acceptance in Australia for nanoparticle siRNA delivery and a granted Japanese patent for RNA immunomodulation.
- TransCode Therapeutics advances patent protection for RNA therapies, potentially improving treatment options for colon, lung, breast, pancreatic, and ovarian cancers.
- TransCode Therapeutics expanded its patent portfolio with approvals in Australia and Japan for RNA-based cancer therapies targeting metastasis and immune pathways.
Impact - Why it Matters
This news matters because it highlights TransCode Therapeutics' growing intellectual property estate, which is crucial for protecting its innovative RNA-based cancer therapies. The granted patents in Australia and Japan not only validate the company's technology but also provide a competitive edge in the global oncology market. For patients, these advancements could lead to novel treatments for hard-to-treat cancers. For investors, the strengthening IP portfolio may signal long-term value and potential partnership opportunities, especially as the company advances its lead candidate TTX-MC138.
Summary
TransCode Therapeutics (NASDAQ: RNAZ) has announced significant advancements in its global intellectual property portfolio, strengthening its position in the competitive field of RNA-based cancer therapeutics. The company received acceptance from IP Australia for Patent Application No. 2019349817, which covers therapeutic nanoparticle compositions designed to deliver small interfering RNA (siRNA) molecules for cancer treatment. The allowed claims encompass nanoparticle compositions and methods of use across a range of cancers, including colon, lung, breast, pancreatic, and ovarian cancers. This Australian patent application is expected to proceed to grant with a projected expiration date of September 6, 2039.
In addition to the Australian milestone, TransCode Therapeutics received a Notice of Allowance from the Japan Patent Office (JPO), followed by the grant and issuance of Japanese Patent No. 7886877. This patent covers RNA-based immunomodulatory compositions designed to selectively activate innate immune pathways within tumors and the tumor microenvironment. The Japanese claims include compositions targeting cancers expressing miR-21 and nanoparticle-enabled delivery approaches incorporating magnetic or polymer-coated systems. These developments underscore TransCode’s commitment to pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers.
TransCode’s lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The company also has a portfolio of other first-in-class therapeutic candidates aimed at mobilizing the immune system to recognize and destroy cancer cells. For investors, the latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ. To view the full press release, visit https://ibn.fm/Pqy4e.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, TransCode Therapeutics Expands Global IP Portfolio with Key Patents
